Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician's Choice Standard-of-Care Chemotherapy.

Hope S RugoJohannes EttlSara Alsterlind HurvitzAnthony GonçalvesKyung-Hun LeeLouis FehrenbacherLida A MinaSami DiabNatasha E WoodwardRinat YerushalmiAnnabel GoodwinJoanne L BlumMiguel MartinRuben G W QuekIulia Cristina TudorHelen BhattacharyyaEric GauthierJennifer K LittonWolfgang Eiermann

Published in: JNCI cancer spectrum (2019)

Across all patient subgroups with gBRCA-mutated advanced breast cancer, talazoparib demonstrated clinically significant superiority in outcomes compared with PCT.

Keyphrases

case report
healthcare
emergency department
primary care
palliative care
quality improvement
metabolic syndrome
radiation therapy
young adults
chronic pain
glycemic control
insulin resistance
decision making